We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

50 hedge funds and large institutions have $12.6M invested in Matinas BioPharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.25% → 0.25% (-0.01%)

7% less capital invested

Capital invested by funds: $13.6M → $12.6M (-$1.01M)

12% less funds holding

Funds holding: 57 → 50 (-7)

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

Holders
50
Holders Change
-7
Holders Change %
-12.28%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
10
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$77.6K
2
MWM
Modera Wealth Management
New Jersey
+$47.8K
3
SS
Simplicity Solutions
Minnesota
+$30.3K
4
Renaissance Technologies
Renaissance Technologies
New York
+$25.7K
5
Northern Trust
Northern Trust
Illinois
+$8.52K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$125K
2
Jane Street
Jane Street
New York
-$74.4K
3
VF
Virtu Financial
New York
-$72K
4
SIG
Sargent Investment Group
Maryland
-$67.2K
5
BCM
Bridgeway Capital Management
Texas
-$50.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$27.2K -$74.4K -2,943 -72%
JP Morgan Chase
27
JP Morgan Chase
New York
$21K – – –
NWMG
28
National Wealth Management Group
Ohio
$20.4K – – –
AWS
29
Atria Wealth Solutions
New York
$18.5K – – –
Morgan Stanley
30
Morgan Stanley
New York
$17.5K -$859 -34 -4%
DAS
31
Dynamic Advisor Solutions
Arizona
$13K -$1.26K -50 -8%
TRCT
32
Tower Research Capital (TRC)
New York
$10K +$2.53K +100 +31%
RPC
33
Rossmore Private Capital
Connecticut
$8.22K – – –
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$6.92K -$7.23K -286 -49%
Osaic Holdings
35
Osaic Holdings
Arizona
$6.67K -$8.59K -340 -54%
CFG
36
Cooper Financial Group
California
$6.53K – – –
CG
37
Clarus Group
Texas
$5.64K – – –
JWCA
38
J.W. Cole Advisors
Florida
$5.05K – – –
SW
39
SlateStone Wealth
Florida
$5K – – –
CFS
40
CRA Financial Services
New Jersey
$4.7K – – –
FAIM
41
Financial Advocates Investment Management
Washington
$4.7K – – –
MFG
42
Magnus Financial Group
New York
$4.7K – – –
Wells Fargo
43
Wells Fargo
California
$3.09K +$25 +1 +0.8%
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$3K +$76 +3 +2%
SPIA
45
Steward Partners Investment Advisory
New York
$1.43K – – –
EWA
46
EverSource Wealth Advisors
Alabama
$1.41K – – –
HFM
47
Hartford Financial Management
Connecticut
$1.18K – – –
IA
48
IFP Advisors
Florida
$383 – – –
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$37 – – –
Commonwealth Equity Services
50
Commonwealth Equity Services
Massachusetts
$13 – – –
1
2
3

MTNB Hedge Fund Activity: Q1 2023 in Review

50 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2023, worth a combined $12.6M — down 7.4% from $13.6M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of MTNB and 2 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $77.6K. The largest seller was BlackRock, cutting an estimated $125K.

  • 50 institutional investors held Matinas BioPharma (MTNB) as of Q1 2023, down from 57 in Q4 2022.
  • Funds reported $12.6M of Matinas BioPharma stock for Q1 2023, down 7.4% quarter-over-quarter.
  • 2 funds opened new Matinas BioPharma positions in Q1 2023 and 9 closed out, a net change of -7 holders.
  • The largest Matinas BioPharma buyer in Q1 2023 was Vanguard Group, an estimated $77.6K added.
  • The largest Matinas BioPharma seller in Q1 2023 was BlackRock, an estimated $125K sold.

Based on aggregated 13F filings for Q1 2023.